Your browser doesn't support javascript.
loading
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.
Polverari, Giulia; Ceci, Francesco; Passera, Roberto; Crane, Jacquelyn; Du, Lin; Li, Gang; Fanti, Stefano; Bernthal, Nicholas; Eilber, Fritz C; Allen-Auerbach, Martin; Czernin, Johannes; Calais, Jeremie; Federman, Noah.
Afiliación
  • Polverari G; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, 200 Medical Plaza, Suite B114-61, Los Angeles, CA, 90095, USA.
  • Ceci F; Nuclear Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.
  • Passera R; PET/CT Center, Affidea IRMET, Turin, Italy.
  • Crane J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, 200 Medical Plaza, Suite B114-61, Los Angeles, CA, 90095, USA.
  • Du L; Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Li G; Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Fanti S; Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Bernthal N; Department of Biostatistics, Jonathan and Karin Fielding of Public Health, University of California at Los Angeles, Los Angeles, CA, USA.
  • Eilber FC; Department of Biostatistics, Jonathan and Karin Fielding of Public Health, University of California at Los Angeles, Los Angeles, CA, USA.
  • Allen-Auerbach M; Nuclear Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.
  • Czernin J; Department of Orthopedics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Calais J; Division of Surgical Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Federman N; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
EJNMMI Res ; 10(1): 122, 2020 Oct 15.
Article en En | MEDLINE | ID: mdl-33063147
INTRODUCTION: This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [18F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX). METHODS: Bone or soft tissue sarcoma patients with (1) baseline [18F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only. RESULTS: Thirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p < 0.02). ΔMTV was associated with tissue response to neo-CTX (p = 0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS. CONCLUSION: [18F]FDG PET/CT performed 6 weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: EJNMMI Res Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: EJNMMI Res Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania